Peter Dull is the deputy director for Integrated Clinical Vaccine Development within the Global Health Division. In this role, he provides technical and strategic guidance on clinical development to the foundation’s program strategy teams, including Pneumonia and Enteric and Diarrheal Diseases, and external partners. In addition, he leads the foundation’s vaccine development activities for HPV vaccines, including efforts with reduced dose schedules.
Peter joined the foundation in 2014 after 10 years at Novartis Vaccines and Diagnostics where he was the clinical franchise head for Meningitis and Sepsis Vaccines. During that time, he led the clinical development and global licensure for a quadrivalent meningococcal glycoconjugate vaccine (Menveo; MenACWY-CRM) as well as a protein-based serogroup B meningococcal vaccine (Bexsero; 4CMenB). His work also included early clinical development of Group B strep glycoconjugate and Staph aureus vaccines. Prior to joining Novartis, he was an epidemic intelligence service officer in the Meningitis and Special Pathogens Branch at the U.S. Centers for Disease Control and completed subspecialty training in infectious diseases at Emory University.
He received his medical degree at University of Wisconsin-Madison and Internal Medicine training at Oregon Health Sciences University.
More about the foundation
Learn about the origins of the foundation and the values that drive our work.
Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.
Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.